Compare GBR & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBR | PRFX |
|---|---|---|
| Founded | 1978 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.1M |
| IPO Year | 1995 | 2020 |
| Metric | GBR | PRFX |
|---|---|---|
| Price | $0.69 | $0.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 69.0K | ★ 232.6K |
| Earning Date | 11-11-2026 | 09-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $155,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.16 | N/A |
| 52 Week Low | $0.62 | $0.58 |
| 52 Week High | $1.31 | $5.39 |
| Indicator | GBR | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 44.19 | 39.06 |
| Support Level | $0.66 | $0.58 |
| Resistance Level | $0.80 | $1.28 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 10.63 | 17.18 |
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.